---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-015230"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:14:50.607219+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotech Q4 revenue down 17% to $45.8M; net loss widens to $69.5M

## Summary
- Full year 2023 revenue $170.3M (-8% YoY); MRD revenue $102.7M (+18%) offset by IM decline.
- clonoSEQ test volume up 53% YoY to 56,496 tests delivered in 2023.
- Net loss $225.3M in 2023 vs $200.4M in 2022; includes $25.4M lease impairment charge.
- Adjusted EBITDA loss $116.4M in 2023 vs $121.6M loss in 2022.
- 2024 MRD revenue guidance $130-140M; total OpEx guided to $360-370M.

## SEC filing metadata
- accession: 0000950170-24-015230
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000095017024015230/0000950170-24-015230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000095017024015230/adpt-20240214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-015230
- JSON: https://secwatch.observer/filing/0000950170-24-015230.json
- Plain text: https://secwatch.observer/filing/0000950170-24-015230.txt

## Key facts
- Earnings Releases
  Adaptive Biotechnologies Corp reported fourth quarter ended December 31, 2023 results: revenue $45.8 million, net income Net loss was $69.5 million.
  - Period: fourth quarter ended December 31, 2023
  - Revenue: $45.8 million
  - Net income: Net loss was $69.5 million
  - Result: reported results
  source text: Revenue was $45.8 million for the quarter ended December 31, 2023, representing a 17% decrease from the fourth quarter in the prior year. MRD revenue was $30.8 million for the quarter, representing a 9% increase from the fourth quarter in the prior year. Immune Medicine revenue was $15.0 million for the quarter, representing a 45% decrease from the fourth quarter in the prior year. Operating expenses, which include a $25.4 million lease impairment charge, were $116.9 million for the fourth quarter of 2023, compared to $94.4 million in the fourth quarter of the prior year, representing an increase of 24%. Excluding the impact of the lease impairment charge, operating expenses for the fourth quarter of 2023 decreased 3% compared to the fourth quarter of the prior year. Interest and other income, net was $4.6 million for the fourth quarter of 2023, compared to $2.6 million in the fourth quarter of the prior year. Interest expense from our revenue interest purchase agreement was $3.0 milli
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000095017024015230/0000950170-24-015230-index.htm
- Earnings Releases
  Adaptive Biotechnologies Corp reported fiscal year 2024 results: revenue between $130 million and $140 million. Guidance initiated.
  - Period: fiscal year 2024
  - Revenue: between $130 million and $140 million
  - Guidance: initiated
  - Result: guidance update
  source text: 2024 Financial Guidance Adaptive Biotechnologies expects full year revenue for the MRD business to be between $130 million and $140 million. No revenue guidance is provided for the Immune Medicine business. We expect full year operating expenses, including cost of revenue, to be between $360 million and $370 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000095017024015230/0000950170-24-015230-index.htm
- Earnings Releases
  Adaptive Biotechnologies Corp reported full year ended December 31, 2023 results: revenue $170.3 million, net income Net loss was $225.3 million.
  - Period: full year ended December 31, 2023
  - Revenue: $170.3 million
  - Net income: Net loss was $225.3 million
  - Result: reported results
  source text: Revenue was $170.3 million for the year ended December 31, 2023, representing an 8% decrease from the prior year. MRD revenue was $102.7 million in 2023, representing an 18% increase from the prior year. Immune Medicine revenue was $67.5 million in 2023, representing a 31% decrease from 2022. Operating expenses for 2023, which include a $25.4 million lease impairment charge, were $397.3 million, compared to $385.5 million for 2022, representing an increase of 3%. Excluding the impact of the lease impairment charge, operating expenses for 2023 decreased 4% compared to the prior year. Interest and other income, net was $15.5 million in 2023, compared to $4.1 million in 2022. Interest expense from our revenue interest purchase agreement was $13.8 million in 2023, compared to $4.2 million in 2022. Net loss was $225.3 million in 2023, compared to $200.4 million in 2022. Adjusted EBITDA (non-GAAP) was a loss of $116.4 million for 2023, compared to a loss of $121.6 million in the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000095017024015230/0000950170-24-015230-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.